Pharmaceutical News and Articles

FDA Issues a Safety Alert for Omalizumab (Marketed as Xolair

ROCKVILLE, Md., July 2, 2007-FDA ALERT [2/2007, updated 7/2007]:  This Alert highlights important revisions to the full prescribing information for Xolair.  The updated full prescribing information for Xolair (July 2007) includes a new Boxed WARNING, updated WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS--Postmarketing Spontaneous Reports.  A New Medication Guide about the risk of anaphylaxis following administration of Xolair is to be distributed with each dose of Xolair..  These revisions address the risk of anaphylaxis following treatment with Xolair.  The implications of this new labeling for healthcare professionals who administer Xolair are summarized below.  Xolair is approved to treat adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. 

Latest Pharma Industry News...

Pharma Industry News Archive

2009: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

MedNotes
Advertisement

(web1)